MedTrace Logo

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

NCT03218917 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2023-03-27

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.

Conditions

  • Non-Cystic Fibrosis Bronchiectasis

Interventions

DRUG

Brensocatib 10 mg

Administered once per day for 24 weeks

DRUG

Brensocatib 25 mg

Administered once per day for 24 weeks

DRUG

Placebo

Administered once per day for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Carlos Fernandez, MD · Insmed Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2019-12-12
Completion
2019-12-12
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Bulgaria
  • Denmark
  • Germany
  • Italy
  • Netherlands
  • New Zealand
  • Poland
  • Singapore
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03218917 on ClinicalTrials.gov